The Japanese brewery giant, which also runs a beverage and health supplement business, said that revenue from APAC was up 1.7 per cent on a currency neutral basis to JPY$89.9bn (US$659m).
APAC ranks second in terms of revenue contribution to the firm, while the domestic market took the top spot with a revenue of JPY$145.8bn (US$1.07bn), which was an increase of 8.8 per cent as compared to last year.
However, segment profit in APAC was down 6.8 per cent on a currency neutral basis to JPY$11.8bn (US$86.5m), “due to the significant impact of negative revenue growth in the health supplement business,” said Noriaki Otsuka, managing executive officer, division COO during the financial results presentation.
Its health supplement business reported a 17.7 per cent decline on a currency neutral basis to JPY$8bn (US$58.6m).
One of the reasons behind the decline in APAC’s health supplement business, was the impact